102 results about "Antibody screening" patented technology

Cancer associated antigens have been identified by autologous antibody screening of libraries of nucleic acids expressed in small cell lung cancer cells using antisera from cancer patients. The invention relates to nucleic acids and encoded polypeptides which are cancer associated antigens expressed in patients afflicted with small cell lung cancer. The invention provides, among other things, isolated nucleic acid molecules, expression vectors containing those molecules and host cells transfected with those molecules. The invention also provides isolated proteins and peptides, antibodies to those proteins and peptides and cytotoxic T lymphocytes which recognize the proteins and peptides. Fragments of the foregoing including functional fragments and variants also are provided. Kits containing the foregoing molecules additionally are provided. The molecules provided by the invention can be used in the diagnosis, monitoring, research, or treatment of conditions characterized by the expression of one or more cancer associated antigens.

The invention relates to antibodies of a coronavirus or antigen binding fragments of the antibodies, a nucleic acid molecule for encoding the antibodies or the antigen binding fragments thereof, a vector including the nucleic acid molecule, a host cell including the vector, and application of the antibodies or the antigen binding fragments thereof to the aspect of preparation of drugs for treatingor preventing diseases caused by the coronavirus, and the aspect of detection products. The inventors utilize a B cell in-vitro monoclonal culture and high-throughput antibody screening technology toobtain a series of antibodies of the coronavirus and the antigen binding fragments of the antibodies, and the antibodies and the antigen binding fragments thereof have high binding capacity and neutralizing capacity for the SARS-CoV-2 virus, can recognize and bind S1 protein of the SARS-CoV-2 virus and a receptor binding domain (RBD) of the S1 protein, and have very strong affinity, and thus, itcan be speculated that the antibodies and the antigen binding fragments possibly have the binding capacity and neutralizing capacity for other coronaviruses, and coronaviruses possibly appearing in the future, and the antibodies and the antigen binding fragments have good clinical application prospects in the future.

The invention relates to a specific antibody of coronavirus or an antigen-binding fragment of the specific antibody, a nucleic acid molecule encoding the antibody or the antigen-binding fragment thereof, a vector comprising the nucleic acid molecule, a host cell comprising the vector, an application of the antibody or the antigen-binding fragment thereof in the preparation of drugs for treating orpreventing diseases caused by coronavirus, and an application of the antibody or the antigen-binding fragment thereof in detection products. The antibody of coronavirus and the antigen-binding fragment of the antibody, which are obtained by inventors through the B cell in-vitro monoclonal culture and high-throughput antibody screening technology, have strong binding capacity and neutralizing capacity on the SARS-CoV-2 virus, can recognize and bind the S1 protein of the SARS-CoV-2 virus and the RBD of the S1 protein, and have very strong affinity. Therefore, it can be speculated that the antibody of coronavirus and the antigen binding fragment of the antibody possibly have binding capacity and neutralizing capacity on other coronaviruses and coronaviruses possibly occurring in the future,and thereby the antibody of coronavirus and the antigen binding fragment of the antibody have good clinical application prospects in the future.

The invention relates to a novel antibody screening method, the method comprises the following steps: (1) anti-body library construction: constructing a heavy chain library of infectable virus particle type antibody and a light chain library of infectable virus particle type antibody; (2) a first screening step: infecting animal cells with the heavy chain library of infectable virus particle type antibody and the light chain library of infectable virus particle type antibody, selecting the animal cells with a specific antibody expression ability by using a specific antigen so as to obtain positive cell strains; (3) a second screening step: obtaining the cDNA sequences of the heavy chain variable region and the light chain variable region of the specific antibody from the positive cell strains, inoculating light chain signal peptide sequence of the specific antibody, inserting an expression vector, and constructing an expression cell strain of the specific antibody so as to prepare the specific antibody through expression. The screening method has the advantages of simple and high efficient technology and practicality. The gene engineering antibody which is obtained through screening has a high specificity and high affinity.

A process for configuring multi-type, high-titer, high-abundance and high-diversity antibody libraries and antigen libraries in procaryotic cell and eukaryotic cell is disclosed, which features use of procaryotic and eukaryotic cell reproduction expression. Its screening features that according to the DNA sequence of antigen epitope gene, the all or part of the open reading frames for antigen gene and the special protein coding gene are combined to form fusion gene for screening the high-specificity and-affinity antibody.

This invention relates to new vaccines against microorganisms based on antigenically mimetic peptides. The invention also relates to methods of discovering such mimetic peptides by first screening peptide-display phage libraries with antibodies against the microbial carbohydrates(s) of interest to locate antigenically mimetic peptides. Vaccines against Group B Streptococcus, or Streptococcus Agalactiae, are preferably produced using this method.

The invention provides a blood type detection quality control product, a preparation method thereof, and application thereof to blood type detection. The blood type detection quality control product comprises 6 bottles of ABO, an RhD blood type detection quality control product, 5 bottles of cross-matching blood quality control products and 4 bottles of irregular antibody sieving test quality control products. The blood type detection quality control product can guarantee accuracy, specificity, affinity and stability of blood type detection, avoids influence on the detection result caused by unqualified detection in the detection process, and creates conditions for accuracy of ABO blood type determination, cross-matching blood and irregular antibody screening.

The invention discloses an epitope-specific antibody screening method, and is used for solving the problem of low screening efficiency of functional antibodies having treatment function in an antibodylibrary screening technology; the method includes the steps of screening of functional epitope peptides and screening of living cells. The invention also provides a fully human anti-PD-1 monoclonal antibody obtained by screening a phage display antibody library by the method; for specific functional epitopes, the fully human anti-PD-1 monoclonal antibody can effectively block the binding of PD-1to a ligand of PD-1, has the characteristics of high affinity and low EC50, and can produce treatment effect on animal models at low dose. The screening efficiency of the functional antibody is greatly improved, and a potential, safer and more economical immunotherapy drug is provided for patients with malignant tumors and immune diseases.

The invention relates to a method for generating a recombinant antibody combining at least one target antigen and the recombinant antibody generated thereby. The antibody generation method provided by the invention combines an optimized high-throughput antibody sequencing method with a hybridoma antibody screening technology, and compared with the traditional hybridoma monoclonal antibody technology, enlarges the selection range of candidate antibody genes, improves the antibody structure optimization efficiency, and increases the possibility of acquiring functional antibodies.

The invention discloses a reliability distribution method and apparatus based on immune genetic optimization, and relates to the field of reliability distribution. The method comprises the following steps: eliminating devices with selected models and devices with determined reliability indexes, and then according to operation working conditions of residual devices, carrying out system reliability modeling; constructing full-life cost function and obtaining a function taking the system full-life cost as an object; and randomly generating initial population, screening antibodies in the population, operating adaptive intersection and variation operation of a genetic algorithm, next, operating an immunization algorithm, extracting a vaccine, vaccinating the antibodies, then classifying the antibodies with higher fitness into new-generation population, determining whether the new-generation population is convergent, if so, outputting a distribution result, and otherwise, returning the antibody screening step. According to the invention, minimization of full-life cost is taken as a distribution object, the immunization algorithm and the genetic algorithm are combined together in a distribution process, and the method and apparatus provided by the invention are applied to task reliability distribution of a complex system.

The invention discloses an antibody screening method based on a single cell chip technology. The method comprises the following steps: 1) expressing a cellular immunized mouse with a special surface antigen and extracting a spleen cell of the mouse for ELISA analysis; 2) attaching the single cell to a cell chip according to the result, and combining the cell chip with fluorescently-labeled antigen to obtain positive clone information and affinity information of antibody; and 3) performing on-site gene amplification on the antibody meeting the standard to obtain an antibody variable region sequence. The method disclosed by the invention can quickly obtain a lot of sequence and affinity data of the antibody. The screening method disclosed by the invention lays a good foundation for pharmaceutical research field.

The invention relates to anti-venomous-snake PLA2 protein antibodies and application thereof. The anti-venomous-snake PLA2 protein antibodies comprise monoclonal antibodies of tritoxomab-PLA2, protoxomab-PLA2, viptoxomab-PLA2, najatoxomab-PLA2 or glotoxomab-PLA2, and have high affinity and specificity. The monoclonal antibodies are prepared by adopting PLA2 proteins of the five kinds of venomous snakes as antigens for immunizing mice through a hybridoma fusion technology, antibody screening is conducted by taking the amino acid sequences of of two hypervariable regions in the PLA2 proteins asantigens, and finally, ten monoclonal antibodies of tritoxomab-PLA2, protoxomab-PLA2, viptoxomab-PLA2, najatoxomab-PLA2 and glotoxomab-PLA2 are obtained in total. One or a combination of more of the ten monoclonal antibodies can be used as a diagnostic test reagent for snake wounds. The anti-venomous-snake PLA2 protein antibodies can be prepared into the diagnostic reagent or kit for the snake wounds, and the diagnostic efficiency of the snake wounds is improved.

The invention provides a clinical blood use application closed-loop management system and method. The method comprises the steps of obtaining a blood type and a test result of a patient and receivingblood transfusion information of the patient from a doctor client; according to a blood transfusion volume, establishing an auditing, signing and issuing configuration process node of a blood transfusion application form and performing graded auditing, signing and issuing; according to a preset specimen barcode generation rule, generating a specimen barcode; according to the specimen barcode, calling a blood type identification result, an antibody screening result and a cross blood matching result of the patient, and when the current information is judged to be consistent with historical information, generating a blood transfusion report; according to the blood transfusion report and a blood bag corresponding to the blood transfusion report, generating a blood distribution form; generatinga blood transfusion process record; and according to a preset blood transfusion medical record template, generating a blood transfusion electronic medical record of the patient in a preset time afterblood transfusion completion. By implementing the method and the system, clinical blood use process information traceability can be ensured, so that clinical blood use reasonability is improved.

The invention provides a construction method of a humanized CD40 gene modified animal model and an application thereof, and relates to the field of gene engineering. The CD40 gene humanized model animal is successfully prepared, the humanized CD40 protein can be normally expressed in the model body, and the product can be used for CD40 gene function research and humanized CD40 antibody screening and evaluation. The animal model prepared by the method can be applied to drug screening, drug effect research, immune related diseases, tumor treatment and the like for human CD40 target sites, the research and development process of new drugs is accelerated, the time and cost are saved, and the drug development risk is reduced. A powerful tool is provided for researching the function of the CD40 protein and screening tumor drugs.

The invention discloses an electronic blood matching method and relates to a technology of medical treatment information diagnosis. Confirmation and information recording are conducted twice on blood types of a blood donator and a patient to sufficiently confirm the matching condition of the blood types of the blood donator and the patient, antibody screening experiments are conducted on the blood donator and the patient to further ensure blood type matching safety and accuracy, and the method greatly improves blood matching efficiency.

The present invention relates to the fields of immunology and diabetes. More specifically, the present invention provides methods and compositions directed to the use of antibodies to quantify cellular pancreatic zinc transporter 8. In certain embodiment, the present invention provides methods and compositions directed to the use of antibodies to screen for modulators of the pancreatic zinc transporter, ZnT8. In one embodiment, a method comprises the steps of (a) permeabilizing human beta cells present in a substrate; (b) contacting the cells with a test agent; and (c) measuring the amount of zinc transporter 8 (ZnT8) using at least one anti-ZnT8 antibody or antigen-binding fragment thereof.

The invention discloses a preparation method of Miltenberger blood group series phenotype red blood cells. The preparation method includes the following steps: step one, adopting monoclonal antibodiesto identify common clinically significant Rh, Kidd, MNS, Duffy, Lewis and P system antigens on Miltenberger blood group positive type O red blood cells; step two, respectively performing PCR-SSP andgene sequencing validation on dose effect antigen C, c, E, e, M, N, S, s, Fya, Fyb, Jka and Jkb to obtain a red blood cell surface antigen pattern; step three, using a red blood cell reagent preservation solution to prepare into a Miltenberger blood group series phenotype red blood cell reagent; and step four, using the prepared Miltenberger blood group series phenotype red blood cell reagent andan existing irregular antibody screening cell reagent to parallelly detect the serum of a hospitalized blood transfusion patient, vertifying the diagnostic performance of the cell reagent, and obtaining a final product. Through the cooperation of the prepared Miltenberger blood group series phenotype red blood cells and the existing screening cells, detection can be performed on Miltenberger bloodgroup related antibodies, and therefore, safe blood transfusion can be guaranteed.